As announced on 18 November 2009, GeneNews has entered into a partnership agreement with a division of Enzo Biochem, Enzo Clinical Labs, to commercialize its ColonSentry in New York and New Jersey, US.

GeneNews president and chief operating officer Gailina Liew said as a risk stratification test, ColonSentry may facilitate a decision to undergo colonoscopy for those who would otherwise refuse the procedure.

"It can also help prioritize patients at greater current risk for colorectal cancer in healthcare systems with limited colonoscopy capacity," Liew added.

"Widespread adoption of the test could lead to earlier detection of colorectal cancer, improved patient outcomes and reduced healthcare costs."